CN104337889A - 一种含蚯蚓的治疗痛风的中药组合物 - Google Patents
一种含蚯蚓的治疗痛风的中药组合物 Download PDFInfo
- Publication number
- CN104337889A CN104337889A CN201410626107.7A CN201410626107A CN104337889A CN 104337889 A CN104337889 A CN 104337889A CN 201410626107 A CN201410626107 A CN 201410626107A CN 104337889 A CN104337889 A CN 104337889A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parts
- gout
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 201000005569 Gout Diseases 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 241001233061 earthworms Species 0.000 title abstract 2
- 239000002994 raw material Substances 0.000 claims abstract description 33
- 241000255789 Bombyx mori Species 0.000 claims abstract description 18
- 241000903946 Clematidis Species 0.000 claims abstract description 13
- 241000243684 Lumbricus Species 0.000 claims description 22
- 230000000694 effects Effects 0.000 abstract description 23
- 229940079593 drug Drugs 0.000 abstract description 12
- 241000361919 Metaphire sieboldi Species 0.000 abstract description 2
- 241000132171 Phryma leptostachya Species 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 16
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 16
- 229940116269 uric acid Drugs 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 240000000971 garden vetch Species 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 241001614060 Amynthas aspergillus Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241001116272 Balsaminaceae Species 0.000 description 1
- 241000255783 Bombycidae Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000218158 Clematis Species 0.000 description 1
- 241000601157 Clematis angustifolia Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000735588 Gaultheria Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001145032 Incarvillea Species 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241000243679 Lumbricidae Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000124449 Paeonia obovata Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001377695 Polygonum arenastrum Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000434639 Speranskia tuberculata Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种中药组合物，具体涉及一种含蚯蚓的治疗痛风的中药组合物，属于医药技术领域。本发明的治疗痛风的中药组合物是由以下重量配比的药用原料制成的药剂：赤芍5～20份、透骨草4～15份、威灵仙4～15份、蚕砂3～10份、蚯蚓3～10份。本发明的治疗痛风的中药组合物，5味药用原料按配比组合后，具有协同增效功能，用于治疗痛风疗效显著，且未发现明显的副作用及不良反应。
Description
技术领域
本发明涉及一种中药组合物，具体涉及一种含蚯蚓的治疗痛风的中药组合物，属于医药技术领域。
背景技术
痛风又称高尿酸血症，发病率高、治愈难、反复发作，属于嘌呤代谢障碍引起的代谢性疾病。痛风多发生于中老年人、肥胖者和脑力劳动者，其临床特点为高尿酸血症及由此引起的痛风性急性关节炎反复发作，痛风石沉积、痛风石性慢性关节炎和关节畸形等，以关节红肿、热痛、反复发作、关节活动不灵活为主要临床表现。常累及肾脏引起慢性间质性肾炎和尿酸肾结石形成。根据血中尿酸增高原因可分为原发性和继发性两大类。原发性痛风的病因是由于先天性嘌呤代谢紊乱所致，属遗传性。继发性痛风的病因，可由肾脏病、白血病、药物、食物等多种原因引起，好发于男性及绝经期女性。
目前用于治疗痛风的西药主要有：秋水仙碱、保泰松或羟基保泰松、消炎痛、布洛芬(ibvprofen，异丁苯丙酸)、炎痛喜康(piroxicanum)、萘普生(naproxen消痛灵)、ACTH及强的松等。但上述药物大多只能稳定病情，不能根治痛风；还会引起严重的副作用造成肝肾功能的损害；即使近期治疗有效也不能控制病情复发，而且可产生耐药性和抵抗性，甚至会出现白细胞减少、心脏功能受损、肝肾功能受损、刺激肠胃系统、再生障碍性贫血、导致糖尿病等合并症。
中医学上，痛风属于“痹证”范畴，《血证论》：“痛风、身体不仁、四肢疼痛、今名痛风、古曰痹证”。越来越多的专家认为，从中医的整体观念出发，用中医药整体辨证施治，不失为治疗痛风疾病的又一条佳径；不但中药本身的毒副作用小，而且可降低西药服用量，克服长期单纯服用西药所带来的巨大毒副作用。
发明内容
本发明的目的在于克服现有技术中所存在西药副作用大、治疗不彻底的上述不足，提供一种治疗痛风的中药组合物，该中药组合物治疗痛风疗效好、见效快，且对患者身体副作用小。
为了实现上述发明目的，本发明提供了以下技术方案：
一种含蚯蚓的治疗痛风的中药组合物，它是由以下重量配比的药用原料制备而成：赤芍5～20份、透骨草4～15份、威灵仙4～15份、蚕砂3～10份、蚯蚓3～10份。所述各种药用原料均为符合国家或地方标准规定的中药材。
优选的，上述药用原料配比中，赤芍所占重量比例为8～15份。更优选的，赤芍所占重量比例为12份。
优选的，上述药用原料配比中，透骨草所占重量比例为7～12份。更优选的，透骨草所占重量比例为9份。
优选的，上述药用原料配比中，威灵仙所占重量比例为7～12份。更优选的，威灵仙所占重量比例为9份。
优选的，上述药用原料配比中，蚕砂所占重量比例为5～8份。更优选的，蚕砂所占重量比例为6份。
优选的，上述药用原料配比中，蚯蚓所占重量比例为5～8份。更优选的，蚯蚓所占重量比例为6份。
本发明的含蚯蚓的治疗痛风的中药组合物，可以按照中药学上常规的提取方法提取药用原料的活性组分，再加上药学上可接受的载体或/和辅料，如淀粉、糊精、微晶纤维、可压性淀粉、硬脂酸镁、微粉硅胶、蔗糖、羧甲基淀粉钠、羟丙基甲基纤维素、植物油、卵磷脂、聚乙二醇、丙二醇、尼泊金乙酯等，制成药剂学上适宜的剂型，如颗粒剂、片剂、硬胶囊、口服液、软胶囊、滴丸、水泛丸等。
本发明的中药组合物的提取方法可以采用但不限于以下方法：
(1)按配方比例取各药用原料并将蚕砂和蚯蚓装袋，向药用原料中加入药用原料体积8～10倍的60～80％乙醇或水；回流提取2～3次；提取时间分别为1～2h；收集合并提取液，并将提取液浓缩成浸膏，干燥，得到本发明的药用原料的提取物。
(2)向上述提取物中加入药用辅料混合制成药剂学上可接受的各种药物剂型。
根据制备各种剂型药物的需要，本发明药物在制备过程中还可加入适当的药用辅料如填充剂、崩解剂、粘合剂、润滑剂、防腐剂等。
与现有技术相比，本发明的有益效果：
本发明含蚯蚓的治疗痛风的中药组合物，是发明人基于祖国医学对痛风的发病机理的认识，根据自己多年临床经验，先从众多中药中确定一系列治疗痛风有效的中药，再经临床反复验证，而筛选出来的。其中，赤芍，别名山芍药、草芍药,为毛茛科植物芍药或川赤芍的干燥根；苦，微寒；归肝经；具有清热凉血、散瘀止痛的功效；用于温毒发斑，吐血衄血，目赤肿痛，肝郁胁痛，经闭痛经，症瘕腹痛，跌扑损伤，痈肿疮疡等症。透骨草，为大戟科地构叶属植物地构叶、凤仙花科草本植物凤仙花、紫葳科角蒿属植物角蒿、豆科野豌豆属植物山野豌豆的全草和杜鹃花科白珠树属植物滇白珠的全株；辛、苦，温，有小毒；归肝、肾经；主祛风除湿、解毒止痛；用于风湿关节痛；外用治疮疡肿毒。威灵仙，为毛茛科植物威灵仙、棉团铁线莲(山蓼)或东北铁线莲(黑薇)的干燥根及根茎；辛、咸，温；归膀胱经；具有祛风除湿、通络止痛的功效；用于风湿痹痛、肢体麻木、筋脉拘挛、屈伸不利、骨哽咽喉等症。蚕砂，别名蚕屎、晚蚕砂、原蚕砂、蚕粪；为蚕蛾科昆虫家蚕的干燥粪便；味甘、辛，性温；归肝、脾、胃经；具有祛风除湿、和胃化浊、活血通经的功效；用于风湿痹痛、肢体不遂、风疹瘙痒、吐泻转筋、闭经、崩漏等症。蚯蚓，别名土龙(《别录》)，地龙子(《药性论》)，为巨蚓科动物参环毛蚓或正蚓科动物背暗异唇蚓等的全体；咸、寒；入肝、脾、肺经；具有清热、平肝、止喘、通络之功效；主治高热狂躁、惊风抽搐、风热头痛、目赤、中风半身不遂、喘息、喉痹、关节疼痛、齿衄、小便不通、疮疡等症。上述五味中草药，药味不多但功能齐备，5味药用原料按所述配比组合后，治疗痛风具有协同增效功能，经临床研究试验，本发明的中药组合物用于治疗痛风疗程短、见效快，给药4天后，即可见效，且疗效显著，患者服药期间未出现明显不良反应。
具体实施方式
下面结合试验例及具体实施方式对本发明作进一步的详细描述，但不应将此理解为本发明上述主题的范围仅限于以下的实施例，凡基于本发明内容所实现的技术均属于本发明的范围。
本发明的实施例和对比例中所用乙醇均为乙醇的水溶液，乙醇的百分含量，如无特殊说明，均为体积百分含量。
实施例1
本实施例的含蚯蚓的治疗痛风的中药组合物，是由以下重量配比的药用原料制备而成：赤芍12g、透骨草9g、威灵仙9g、蚕砂6g、蚯蚓6g。
上述药用原料的提取方法：
(1)按配方比例取各药用原料并将蚕砂和蚯蚓装袋，向药用原料中加入药用原料体积8～10倍的60～80％乙醇或水，回流提取2～3次；提取时间分别为1～2h；收集合并提取液，并将提取液浓缩至相对密度1.20(80℃)，得到本实施例药用原料的提取物。
(2)向上述提取物中加入提取物重量2倍重量的可溶性淀粉，制粒，干燥，分装成袋，得到颗粒剂。
实施例2
本实施例的含蚯蚓的治疗痛风的中药组合物，是由以下重量配比的药用原料制备而成：赤芍20g、透骨草12g、威灵仙4g、蚕砂3g、蚯蚓10g。
按实施例1中药用原料提取方法提取本实施例药用原料的活性组分，得到实施例2治疗痛风的中药组合物。
实施例3
本实施例的含蚯蚓的治疗痛风的中药组合物，是由以下重量配比的药用原料制备而成：赤芍14g、透骨草10g、威灵仙8g、蚕砂8g、蚯蚓6g。
按实施例1中药用原料提取方法提取本实施例药用原料的活性组分，得到实施例3治疗痛风的中药组合物。
对比例
本对比例的治疗痛风的中药组合物，是由以下重量配比的药用原料制备而成：赤芍12g、透骨草9g、威灵仙9g、蚕砂6g。
按实施例1中药用原料提取方法提取本对比例药用原料的活性组分，得到对比例治疗痛风的中药组合物。
药效学和毒性试验：
为了证实本发明药物的疗效和安全性，发明人进行了药效学和毒性试验考察。所采用的研究方法及试验结果如下：
1、试验材料
(1)药物及试剂：
根据实施例1制备的实施例1的中药组合物；
根据对比例制备的对比例的中药组合物；
秋水仙碱：为云南植物药业有限公司产品。
(2)动物：昆明种小鼠，由四川抗菌素研究所实验动物中心提供。
2、试验方法与结果
(1)对高尿酸血症小鼠血尿酸水平的影响
取昆明种小鼠50只，雌雄皆用，体重18～22g，随机分为五组，每组10只，第一组为生理盐水组，第二组为本发明药物实验组(8g生药材/kg)，第三组为阳性对照组，第四组为对照组1，第五组为模型组。
对第一组按8g/kg的剂量灌服生理盐水，第二组按8g生药材/kg的剂量灌服本发明实施例1制备的中药组合物，第三组按0.1mg/kg的药剂剂量灌服秋水仙碱，第四组按8g生药材/kg的剂量灌服对比例制备的中药组合物，第五组不作任何处理，每日1次，连续4d。
末次给药1h后，除生理盐水组外，其余各组，即第二组到第五组，动物腹腔注射次黄嘌呤1mg/kg，造成小鼠高血尿酸，生理盐水组按1mg/kg注射生理盐水。注射后0.5h，对各组动物摘眼球取血，将取得的血液在3000r/min的转速条件下离心15min后，取血清测血尿酸值。表1为各实验组和对照组经处理后，血尿酸测量值的统计结果。
表1
注：与模型组比较:**P<0.01；与对照组1比较:▲▲P<0.01。
表1中,本发明药物实验组测得血尿酸值为170±21umol/l：与生理盐水组的血尿酸值134±27umol/l及阳性对照组的血尿酸值156±25umol/l接近；相对模型组测得的血尿酸值752±83umol/l降低了580umol/l左右，且本发明药物实验组的统计结果相对于模型组P<0.01，具有显著性差异；本发明治疗痛风的中药组合物治疗痛风具有很好的疗效。
而表1中,对照组1测得血尿酸值为269±39umol/l，相对本发明药物实验组测得血尿酸值为170±21umol/l高出近100umol/l。且本发明药物实验组的血尿酸测量值较对照组1的血尿酸测量值P＜0.01，具有显著性差异。由此得知，5种药用原料按所述重量配比组合后，具有协同增效功能，能显著提高中药组合物的疗效，缺少任意组分，中药组合物的疗效均显著下降。
综上所述，本发明含蚯蚓的治疗痛风的中药组合物，治疗痛风的疗程短，见效快，给药4天即可见效，疗效显著。给药4天后注射次黄嘌呤，本发明药物实验组的血尿酸测量值均不会发生显著升高现象；5种药用原料按所述重量配比组合后，具有协同增效功能，能显著提高中药组合物的疗效。缺少任意组分，其疗效均显著下降，如对照组1，注射次黄嘌呤后，测得血尿酸值相对本发明药物实验组的血尿酸测量值升高近100umol/l。
Claims (10)
1.一种含蚯蚓的治疗痛风的中药组合物，其特征在于：它是由以下重量配比的药用原料制备而成：赤芍5～20份、透骨草4～15份、威灵仙4～15份、蚕砂3～10份、蚯蚓3～10份。
2.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：赤芍所占重量比例为8～15份。
3.根据权利要求2所述的治疗痛风的中药组合物，其特征在于：赤芍所占重量比例为12份。
4.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：透骨草所占重量比例为7～12份。
5.根据权利要求4所述的治疗痛风的中药组合物，其特征在于：透骨草所占重量比例为9份 。
6.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：威灵仙所占重量比例为7～12份。
7.根据权利要求6所述的治疗痛风的中药组合物，其特征在于：威灵仙所占重量比例为9份。
8.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：蚕砂所占重量比例为5～8份。
9.根据权利要求8所述的治疗痛风的中药组合物，其特征在于：蚕砂所占重量比例为6份。
10.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：蚯蚓所占重量比例为5～8份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626107.7A CN104337889B (zh) | 2014-11-07 | 2014-11-07 | 一种含蚯蚓的治疗痛风的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626107.7A CN104337889B (zh) | 2014-11-07 | 2014-11-07 | 一种含蚯蚓的治疗痛风的中药组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104337889A true CN104337889A (zh) | 2015-02-11 |
| CN104337889B CN104337889B (zh) | 2016-07-13 |
Family
ID=52494881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410626107.7A Active CN104337889B (zh) | 2014-11-07 | 2014-11-07 | 一种含蚯蚓的治疗痛风的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104337889B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940750A (zh) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | 治疗痛风的药物组合物 |
| JP2013209363A (ja) * | 2012-02-29 | 2013-10-10 | Saiko Corporation:Kk | キサンチンオキシダーゼ阻害剤 |
-
2014
- 2014-11-07 CN CN201410626107.7A patent/CN104337889B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013209363A (ja) * | 2012-02-29 | 2013-10-10 | Saiko Corporation:Kk | キサンチンオキシダーゼ阻害剤 |
| CN102940750A (zh) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | 治疗痛风的药物组合物 |
Non-Patent Citations (1)
| Title |
|---|
| 陈东银: "《痛风合理用药与食疗》", 31 August 2014, 金盾出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104337889B (zh) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104918628A (zh) | 一种治疗生殖系统癌症的药物组合及其制备方法 | |
| CN104338062A (zh) | 一种治疗腹痛、腹泻的中药制剂 | |
| CN103784890A (zh) | 一种治疗骨病的中药组合物 | |
| CN104815318A (zh) | 一种治疗痛风的中药制剂 | |
| CN104027684A (zh) | 一种治疗痛风的中药组合物及其制备方法 | |
| CN104435567A (zh) | 一种含绞股蓝的治疗痛风的中药组合物 | |
| CN104337989A (zh) | 一种含鹅不食草和乳香的治疗痛风的中药组合物 | |
| CN103610795B (zh) | 一种杜仲降压口服制剂的制备方法 | |
| CN104547902A (zh) | 中药制剂用于制备治疗慢性肠炎、阑尾炎药物中的用途 | |
| CN104225507A (zh) | 一种治疗脑溢血所致的肢体麻痹和疼痛的中药 | |
| CN104337909B (zh) | 一种含九香虫的治疗痛风的中药组合物 | |
| CN104095940B (zh) | 一种治疗痛风的中药组合物 | |
| CN104721629B (zh) | 一种治疗小儿缺铁性贫血的中药制剂及制备方法 | |
| CN104337889B (zh) | 一种含蚯蚓的治疗痛风的中药组合物 | |
| CN112472776A (zh) | 一种治疗痛风的中药丸剂及其制备方法 | |
| CN104435079A (zh) | 一种治疗痛风的中药组合物 | |
| CN104352672A (zh) | 一种含龟板的治疗糖尿病的中药组合物 | |
| CN104337898B (zh) | 一种含郁李仁的治疗痛风的中药组合物 | |
| CN110478416A (zh) | 治疗风湿性类风湿性关节炎的组合物及其制备方法和应用 | |
| CN104740405B (zh) | 一种治疗过敏性紫癜性肾损害的中药制剂及制备方法 | |
| CN111658748A (zh) | 用于治疗痛经的组合物、口服制剂及应用 | |
| CN103816486A (zh) | 一种治疗急慢性肝炎的中药制剂 | |
| CN104436017A (zh) | 一种含木通的治疗痛风的中药组合物 | |
| CN102335304B (zh) | 一种祛风燥湿活血止痛的中药组合物及其制备方法 | |
| CN105796666A (zh) | 一种抗腹泻的中药组合物及制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 610041, No. 12, 9, 911, 88 South Garden Road, Chengdu hi tech Zone, Sichuan, China Patentee after: Chengdu medical road Kang Huaxi medical science and Technology Co Ltd Address before: 610000, No. 12, 9, 911, 88 South Garden Road, Chengdu hi tech Zone, Sichuan, China Patentee before: CHENGDU HUAXI TECHNOLOGY CO., LTD. |
|
| CP03 | Change of name, title or address |